IFM Investors Pty Ltd boosted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 9.0% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 57,878 shares of the medical instruments supplier's stock after purchasing an additional 4,792 shares during the period. IFM Investors Pty Ltd's holdings in Becton, Dickinson and Company were worth $13,954,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in shares of Becton, Dickinson and Company by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 26,743,052 shares of the medical instruments supplier's stock valued at $6,067,196,000 after acquiring an additional 184,288 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its holdings in shares of Becton, Dickinson and Company by 36.1% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 12,126,707 shares of the medical instruments supplier's stock valued at $2,751,187,000 after acquiring an additional 3,219,317 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Becton, Dickinson and Company by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 6,351,537 shares of the medical instruments supplier's stock valued at $1,437,161,000 after acquiring an additional 66,024 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in shares of Becton, Dickinson and Company by 15.1% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 6,175,899 shares of the medical instruments supplier's stock valued at $1,401,126,000 after acquiring an additional 810,345 shares in the last quarter. Finally, First Eagle Investment Management LLC boosted its holdings in shares of Becton, Dickinson and Company by 31.4% in the fourth quarter. First Eagle Investment Management LLC now owns 4,426,022 shares of the medical instruments supplier's stock valued at $1,004,132,000 after acquiring an additional 1,057,879 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company's stock.
Becton, Dickinson and Company Price Performance
BDX traded up $1.65 during midday trading on Tuesday, reaching $174.60. 1,908,132 shares of the company's stock were exchanged, compared to its average volume of 2,069,888. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.13 and a quick ratio of 0.64. The stock has a market capitalization of $50.04 billion, a PE ratio of 33.32, a P/E/G ratio of 1.31 and a beta of 0.25. The business's 50-day moving average price is $172.66 and its 200 day moving average price is $206.96. Becton, Dickinson and Company has a 1-year low of $163.33 and a 1-year high of $251.99.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.28 by $0.07. The company had revenue of $5.27 billion during the quarter, compared to analysts' expectations of $5.35 billion. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The firm's quarterly revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.17 earnings per share. As a group, equities analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.
Becton, Dickinson and Company Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Monday, June 30th. Shareholders of record on Monday, June 9th were given a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 2.38%. The ex-dividend date of this dividend was Monday, June 9th. Becton, Dickinson and Company's payout ratio is currently 79.39%.
Analysts Set New Price Targets
Several brokerages have recently weighed in on BDX. Stifel Nicolaus lowered their target price on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. William Blair cut shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research note on Thursday, May 1st. Citigroup cut shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and reduced their price objective for the company from $217.00 to $185.00 in a research note on Thursday, May 22nd. Morgan Stanley reduced their price objective on shares of Becton, Dickinson and Company from $280.00 to $196.00 and set an "overweight" rating for the company in a research note on Tuesday, May 6th. Finally, Wells Fargo & Company cut shares of Becton, Dickinson and Company from an "overweight" rating to an "equal weight" rating in a research note on Thursday, May 1st. Eight equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $219.22.
Check Out Our Latest Research Report on Becton, Dickinson and Company
Insider Transactions at Becton, Dickinson and Company
In other news, EVP David Shan sold 1,166 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total value of $199,607.54. Following the completion of the transaction, the executive vice president owned 4,575 shares of the company's stock, valued at $783,194.25. The trade was a 20.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Michael David Garrison sold 479 shares of the business's stock in a transaction that occurred on Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total transaction of $94,497.12. Following the completion of the transaction, the executive vice president directly owned 4,887 shares of the company's stock, valued at approximately $964,107.36. This represents a 8.93% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.36% of the company's stock.
Becton, Dickinson and Company Profile
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Further Reading
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
